European journal of neurology · 2026
Diagnostic and Prognostic Utility of Plasma p-tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Ruixian, Yang Jie, Chai Wenhui, Liu Hongwei, Wang Xuanqian, Zhang Shuyu, Cai Hongtao, Wang Jinghua, Guo Tengfei, Han Ying
Аннотация
BACKGROUND: Plasma phosphorylated tau 217 (p-tau217) has emerged as a promising Alzheimer's disease (AD) biomarker, yet its longitudinal associations with neurodegeneration and cognitive decline remain inadequately characterized in Chinese populations, and ethnicity-specific diagnostic thresholds are lacking for optimal clinical application.
METHODS: A total of 541 participants (402 cognitively unimpaired [CU]; 139 cognitively impaired [CI]) from the Sino Longitudinal Study on Cognitive Decline (SILCODE) cohort were enrolled. Cross-sectional and longitudinal associations of plasma p-tau217 with amyloid-β (Aβ) pathology, neurodegeneration, and cognition were evaluated. Diagnostic thresholds were derived using receiver operating characteristic analysis, and Cox regression assessed prognostic value for clinical progression.
RESULTS: Cross-sectionally, baseline p-tau217 was associated with greater Aβ burden, neurodegeneration, and poorer cognition in the whole cohort and CI group; in the CU group, associations were confined to amyloid measures. Longitudinally, accelerated p-tau217 accumulation was associated with faster neurodegeneration and cognitive decline in the whole cohort, with stage-dependent patterns: nominal associations with neurodegenerative markers in CU and prominent cognitive associations in CI. Plasma p-tau217 demonstrated high diagnostic accuracy for amyloid positivity (AUC = 0.891; cutoff: 0.529 pg/mL). Threshold-based stratification effectively differentiated individuals by Aβ burden, neurodegeneration, and cognitive trajectories. Elevated baseline p-tau217 predicted higher progression risk (Whole cohort: HR = 2.66 [1.28-5.53], p = 0.009; CU: HR = 2.44 [1.07-5.59], p = 0.034).
CONCLUSION: Plasma p-tau217 serves as a valuable diagnostic and prognostic biomarker for AD, even among CU individuals, and the ethnicity-specific threshold of 0.529 pg/mL enhances its clinical applicability for early detection and risk stratification in Chinese populations.
METHODS: A total of 541 participants (402 cognitively unimpaired [CU]; 139 cognitively impaired [CI]) from the Sino Longitudinal Study on Cognitive Decline (SILCODE) cohort were enrolled. Cross-sectional and longitudinal associations of plasma p-tau217 with amyloid-β (Aβ) pathology, neurodegeneration, and cognition were evaluated. Diagnostic thresholds were derived using receiver operating characteristic analysis, and Cox regression assessed prognostic value for clinical progression.
RESULTS: Cross-sectionally, baseline p-tau217 was associated with greater Aβ burden, neurodegeneration, and poorer cognition in the whole cohort and CI group; in the CU group, associations were confined to amyloid measures. Longitudinally, accelerated p-tau217 accumulation was associated with faster neurodegeneration and cognitive decline in the whole cohort, with stage-dependent patterns: nominal associations with neurodegenerative markers in CU and prominent cognitive associations in CI. Plasma p-tau217 demonstrated high diagnostic accuracy for amyloid positivity (AUC = 0.891; cutoff: 0.529 pg/mL). Threshold-based stratification effectively differentiated individuals by Aβ burden, neurodegeneration, and cognitive trajectories. Elevated baseline p-tau217 predicted higher progression risk (Whole cohort: HR = 2.66 [1.28-5.53], p = 0.009; CU: HR = 2.44 [1.07-5.59], p = 0.034).
CONCLUSION: Plasma p-tau217 serves as a valuable diagnostic and prognostic biomarker for AD, even among CU individuals, and the ethnicity-specific threshold of 0.529 pg/mL enhances its clinical applicability for early detection and risk stratification in Chinese populations.